Health and Healthcare Systems

This breakthrough design could potentially lead to an HIV vaccine

A veterinarian prepares a dosage of rabies vaccine at the 2014 Taipei Pet Show at Nangang Exhibition Hall in Taipei July 11, 2014. The show runs from July 11 to 14. REUTERS/Pichi Chuang (TAIWAN - Tags: SOCIETY DRUGS) - RTR3Y3TS

The results are an important step toward developing a vaccine against HIV and other chronic infections. Image: REUTERS/Pichi Chuang

Richard Steed
Communications Adviser, Novo Nordisk Foundation Center for Basic Metabolic Research, Copenhagen

A new approach to vaccine design could lead to one for HIV, say researchers, who have tested their work in monkeys.

Traditional vaccines typically cause a strong stimulation of the parts of the immune system that are most responsive to the specific virus. But the reaction to the vaccine and the infection is often so intense that the immune system “loses momentum” and consequently can’t completely eliminate the virus.

Researchers have therefore designed a vaccine that boosts the cells of the immune system responsible for the less exposed parts of the virus. As a result, the cells can distribute the “work load” and keep up defense against the virus attack for longer. This gives the immune system time to build a more efficient defense, which may then defeat the last of the virus.

Image: Reuters

“We’re presenting an entirely new vaccine solution,” says Peter Holst, research team leader and associate professor in the immunology and microbiology department at the University of Copenhagen.

“Our vaccine supports the work of the immune system in developing an effective combating mechanism against the virus, rather than immediately combating the toughest parts of the virus. In combination with other vaccines, this approach can prove to have a highly efficient effect.”

The results show that this technology can control the SIV virus infection (simian immunodefiency virus) in monkeys. SIV is a chronic infectious disease and a highly realistic representation of HIV. The results are an important step toward developing a vaccine against HIV and other chronic infections.

“The next phase of our work is to build virus control in all infected animals and later in humans. We’re convinced that it’s possible to identify further improvements in our experiments and thus achieve a well-functioning vaccine, initially against HIV, but also against other chronic infections,” says Holst.

The study appears in the journal EbioMedicine. Support came from the Danish AIDS Foundation and the Danish Council for Independent Research.

Don't miss any update on this topic

Create a free account and access your personalized content collection with our latest publications and analyses.

Sign up for free

License and Republishing

World Economic Forum articles may be republished in accordance with the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Public License, and in accordance with our Terms of Use.

The views expressed in this article are those of the author alone and not the World Economic Forum.

Stay up to date:

Global Health

Share:
The Big Picture
Explore and monitor how Global Health is affecting economies, industries and global issues
World Economic Forum logo

Forum Stories newsletter

Bringing you weekly curated insights and analysis on the global issues that matter.

Subscribe today

These collaborations are already tackling climate-driven health risks but more can be done to find solutions

Fernando J. Gómez and Elia Tziambazis

December 20, 2024

Investing in children’s well-being: The urgent need for expanded mental health and psychosocial support funding

About us

Engage with us

  • Sign in
  • Partner with us
  • Become a member
  • Sign up for our press releases
  • Subscribe to our newsletters
  • Contact us

Quick links

Language editions

Privacy Policy & Terms of Service

Sitemap

© 2024 World Economic Forum